Cargando…
Considerations in the Preclinical Assessment of the Safety of Antisense Oligonucleotides
The nucleic acid therapeutics field has made tremendous progress in the past decades. Continuous advances in chemistry and design have led to many successful clinical applications, eliciting even more interest from researchers including both academic groups and drug development companies. Many precl...
Autores principales: | Goyenvalle, Aurélie, Jimenez-Mallebrera, Cecilia, van Roon, Willeke, Sewing, Sabine, Krieg, Arthur M., Arechavala-Gomeza, Virginia, Andersson, Patrik |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Mary Ann Liebert, Inc., publishers
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9940817/ https://www.ncbi.nlm.nih.gov/pubmed/36579950 http://dx.doi.org/10.1089/nat.2022.0061 |
Ejemplares similares
-
Therapeutic Potential of Tricyclo-DNA antisense oligonucleotides
por: Goyenvalle, Aurelie, et al.
Publicado: (2016) -
Delivery is key: lessons learnt from developing splice‐switching antisense therapies
por: Godfrey, Caroline, et al.
Publicado: (2017) -
Delivery of oligonucleotide‐based therapeutics: challenges and opportunities
por: Hammond, Suzan M, et al.
Publicado: (2021) -
Consensus Guidelines for the Design and In Vitro Preclinical Efficacy Testing N-of-1 Exon Skipping Antisense Oligonucleotides
por: Aartsma-Rus, Annemieke, et al.
Publicado: (2023) -
Experimental Model Systems Used in the Preclinical Development of Nucleic Acid Therapeutics
por: Zhou, Haiyan, et al.
Publicado: (2023)